Šalis: Izraelis
kalba: anglų
Šaltinis: Ministry of Health
LAMIVUDINE
GLAXO SMITH KLINE (ISRAEL) LTD
J05AF05
SOLUTION (ORAL)
LAMIVUDINE 5 MG/ML
PER OS
Required
GLAXO SMITH KLINE INC., CANADA
LAMIVUDINE
LAMIVUDINE
Zeffix is indicated for the treatment of chronic hepatitis B associated with the evidence of hepatitis B viral (HBV) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.
2013-10-31
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed with a physician’s prescription only ZEFFIX ORAL SOLUTION Each 1 ml of oral solution contains 5 mg lamivudine. For the list of inactive and allergenic ingredients, see section 2 - “Important information about some of the ingredients of the medicine” and section 6 - “Further information”. READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the physician or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar. This medicine is intended for adults and children above the age of 2 years. 1. WHAT IS THE MEDICINE INTENDED FOR? Zeffix is a medicine used to treat chronic hepatitis B virus (HBV) in adults and children above the age of 2 years. THERAPEUTIC GROUP: Nucleoside analogue reverse transcriptase inhibitors (_NRTIs_). It is not known if Zeffix is safe and effective for: ∙ people with chronic HBV who have a severely damaged liver that is unable to work properly (decompensated liver disease) ∙ people with HIV-1, hepatitis C virus or hepatitis D (delta) virus ∙ people who have had a liver transplant 2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE IF: you are sensitive (allergic) to lamivudine or to any of the additional ingredients contained in the medicine (listed in section 6). SPECIAL WARNINGS REGARDING USE OF THIS MEDICINE BEFORE BEGINNING TREATMENT WITH ZEFFIX, TELL YOUR PHYSICIAN ABOUT ALL OF YOUR HEALTH CONDITIONS, INCLUDING IF: ∙ You have an HIV-1 infection. ∙ You have kidney problems. ∙ You have diabetes. Each 20 ml (100 mg) dose of Zeffix Oral Solution contains 4 grams sucrose. ∙ You are pregnant or plan to become pregnant. It is not known whether Zeffix will harm your unborn baby. ∙ You are breastfeeding or plan to breastfeed. Ze Perskaitykite visą dokumentą
Page 1 of 20 ZEFFIX TABLETS ZEFFIX ORAL SOLUTION WARNING: EXACERBATIONS OF HEPATITIS B AND RISK OF HIV-1 RESISTANCE IF ZEFFIX IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION SEVERE ACUTE EXACERBATIONS OF HEPATITIS B HAVE BEEN REPORTED IN PATIENTS WHO HAVE DISCONTINUED ANTI-HEPATITIS B THERAPY (INCLUDING ZEFFIX). HEPATIC FUNCTION SHOULD BE MONITORED CLOSELY WITH BOTH CLINICAL AND LABORATORY FOLLOW-UP FOR AT LEAST SEVERAL MONTHS IN PATIENTS WHO DISCONTINUE ANTI-HEPATITIS B THERAPY. IF APPROPRIATE, INITIATION OF ANTI-HEPATITIS B THERAPY MAY BE WARRANTED _[SEE _ _WARNINGS AND PRECAUTIONS (5.1)]. _ ZEFFIX IS NOT APPROVED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION BECAUSE THE LAMIVUDINE DOSAGE IN ZEFFIX IS SUBTHERAPEUTIC AND MONOTHERAPY IS INAPPROPRIATE FOR THE TREATMENT OF HIV-1 INFECTION. HIV-1 RESISTANCE MAY EMERGE IN CHRONIC HEPATITIS B-INFECTED PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION. HIV COUNSELING AND TESTING SHOULD BE OFFERED TO ALL PATIENTS BEFORE BEGINNING TREATMENT WITH ZEFFIX AND PERIODICALLY DURING TREATMENT _[SEE WARNINGS AND PRECAUTIONS (5.2)]_. 1 INDICATIONS AND USAGE ZEFFIX is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old. _See Clinical _ _Studies (14.1, 14.2)_ . _ _ The following points should be considered when initiating therapy with ZEFFIX: • Due to high rates of resistance development in treated patients, initiation of treatment with ZEFFIX should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • ZEFFIX has not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. • ZEFFIX has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infe Perskaitykite visą dokumentą